These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24764582)

  • 1. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
    Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS
    Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.
    Németh A; Bányai GL; Dobos NK; Kós T; Gaál A; Varga Z; Buzás EI; Khamari D; Dank M; Takács I; Szász AM; Garay T
    Cell Commun Signal; 2024 May; 22(1):282. PubMed ID: 38778340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.
    Doxie DB; Greenplate AR; Gandelman JS; Diggins KE; Roe CE; Dahlman KB; Sosman JA; Kelley MC; Irish JM
    Pigment Cell Melanoma Res; 2018 Nov; 31(6):708-719. PubMed ID: 29778085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
    Schilling B; Sondermann W; Zhao F; Griewank KG; Livingstone E; Sucker A; Zelba H; Weide B; Trefzer U; Wilhelm T; Loquai C; Berking C; Hassel J; Kähler KC; Utikal J; Al Ghazal P; Gutzmer R; Goldinger SM; Zimmer L; Paschen A; Hillen U; Schadendorf D;
    Ann Oncol; 2014 Mar; 25(3):747-753. PubMed ID: 24504444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
    Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
    Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
    Lai X; Friedman A
    BMC Syst Biol; 2017 Jul; 11(1):70. PubMed ID: 28724377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
    Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
    Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near complete remission of an inoperable pancreatic acinar cell carcinoma after BRAF-/MEK-inhibitor treatment-A case report and review of the literature.
    von Fritsch L; von Bubnoff N; Weber K; Kirfel J; Schreiber C; Keck T; Wellner U
    Genes Chromosomes Cancer; 2024 Feb; 63(2):e23222. PubMed ID: 38340027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1.
    Hu R; Hou H; Li Y; Zhang M; Li X; Chen Y; Guo Y; Sun H; Zhao S; Liao M; Cao D; Yan Q; Chen X; Yin M
    Theranostics; 2024; 14(2):593-607. PubMed ID: 38169595
    [No Abstract]   [Full Text] [Related]  

  • 10. Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.
    De Carli A; Kapelyukh Y; Kursawe J; Chaplain MAJ; Wolf CR; Hamis S
    NPJ Syst Biol Appl; 2024 May; 10(1):51. PubMed ID: 38750040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell-Based Cancer Vaccine.
    Guo J; Muse E; Christians AJ; Swanson SJ; Davila E
    Cancer Immunol Res; 2019 Sep; 7(9):1523-1534. PubMed ID: 31266784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.
    Meraz-Torres F; Niessner H; Plöger S; Riel S; Schörg B; Casadei N; Kneilling M; Schaller M; Flatz L; Macek B; Eigentler T; Rieß O; Garbe C; Amaral T; Sinnberg T
    J Exp Clin Cancer Res; 2024 Jan; 43(1):30. PubMed ID: 38263136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exceptional Response of
    Kerle IA; Scheuble AM; Kobitzsch B; Stocker G; Hiller GGR; Badendick M; William D; Krueger A; Gross T; Koegler A; Hartig A; Richter D; Aust DE; Schroeck E; Heining C; Glimm H; Hacker UT
    JCO Precis Oncol; 2024 May; 8():e2400030. PubMed ID: 38820503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
    Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation.
    Wiemer AJ; Wernimont SA; Cung TD; Bennin DA; Beggs HE; Huttenlocher A
    Biochem Pharmacol; 2013 Sep; 86(6):770-81. PubMed ID: 23928188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Balancing immune responses - multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma.
    Pape K; Protopapa M; Schraad M; Steffen F; Zipp F; Bittner S
    Front Oncol; 2023; 13():1303141. PubMed ID: 38074649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.
    Dennison L; Mohan AA; Yarchoan M
    Curr Oncol Rep; 2021 Feb; 23(2):23. PubMed ID: 33547983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
    Sidaway P
    Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
    [No Abstract]   [Full Text] [Related]  

  • 19. Dabrafenib Promotes Schwann Cell Differentiation by Inhibition of the MEK-ERK Pathway.
    Park K; Shin Y; Lee G; Park H; Choi Y
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma.
    Yuan L; Mishra R; Patel H; Abdulsalam S; Greis KD; Kadekaro AL; Merino EJ; Garrett JT
    J Cancer; 2018; 9(24):4665-4676. PubMed ID: 30588251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.